Investigation of anti-Parkinson activity of dicyclomine 

References

• Prakash K, Bannur B, Chavan MD, et al. Neuroanatomical changes in Parkinson’s disease in relation to cognition: an update. J Adv Pharm Technol Res. 2016;7(4):123–126.
   PubMed Web of Science ®Google Scholar
• Moisan F, Kab S, Mohamed F, et al. Parkinson disease male-to-female ratios increase with age: French nationwide study and meta-analysis. J Neurol Neurosurg Psychiatry. 2016;87(9):952–957.
   PubMed Web of Science ®Google Scholar
• Zaidi AA, Khan TA, Shakir L, et al. Evaluation of C. cassia effectiveness in behavioral modulation of haloperidol induced Parkinson’s disease (mice model). Br J Pharm Res. 2016;6:1–7.
   Google Scholar
• DeMaagd G, Philip A. Parkinson’s disease and its management: part 1: disease entity, risk factors, pathophysiology, clinical presentation, and diagnosis. P&T. 2015;40(8):504–532.
   PubMedGoogle Scholar
• Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson’s disease: dopaminergic pathophysiology and treatment. Lancet Neurol. 2009;8(5):464–474.
   PubMed Web of Science ®Google Scholar
• Sunday OP, Adekunle MF, Temitope OT, et al. Alteration in antioxidants level and lipid peroxidation of patients with neurodegenerative diseases {Alzheimer’s disease and Parkinson disease}. Int J Nutr Pharmacol Neurol Dis. 2014;4(3):146.
   Google Scholar
• Grăciun EC, Dronca E, Leach NV. Antioxidant enzymes activity in subjects with Parkinson’s disease under L-DOPA therapy. Human Vet Med. 2016;8(2):124–127.
   Google Scholar
• Mallajosyula JK, Kaur D, Chinta SJ, et al. MAO-B elevation in mouse brain astrocytes results in Parkinson’s pathology. PLoS One. 2008;3(2):e1616.
   PubMed Web of Science ®Google Scholar
• Youdim M, Collins G, Sandler M, et al. Biological sciences: human brain monoamine oxidase: multiple forms and selective inhibitors. Nature. 1972;236(5344):225–228.
   PubMed Web of Science ®Google Scholar
• Youdim MB, Buccafusco JJ. Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol Sci. 2005;26(1):27–35.
   PubMed Web of Science ®Google Scholar
• López-Sendón J, Mena MA, de Yébenes JG. Drug-induced parkinsonism. Expert Opin Drug Saf. 2013;12(4):487–496.
   PubMed Web of Science ®Google Scholar
• McCormack AL, Atienza JG, Johnston LC, et al. Role of oxidative stress in paraquat-induced dopaminergic cell degeneration. J Neurochem. 2005;93(4):1030–1037.
   PubMed Web of Science ®Google Scholar
• Corwin C. Insights into the cyclooxygenase pathway in a progressive rat model of Parkinson’s disease induced by prostaglandin J2: protection with ibuprofen [dissertation]. New York (NY): City University of New York; 2018.
   Google Scholar
• Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol. 1999;56(1):33–39.
   PubMed Web of Science ®Google Scholar
• Miyakawa T, Yamada M, Duttaroy A, et al. Hyperactivity and intact hippocampus-dependent learning in mice lacking the M1 muscarinic acetylcholine receptor. J Neurosci. 2001;21(14):5239–5250.
   PubMed Web of Science ®Google Scholar
• Shin SS, Dixon CE. Alterations in cholinergic pathways and therapeutic strategies targeting cholinergic system after traumatic brain injury. J Neurotrauma. 2015;32(19):1429–1440.
   PubMed Web of Science ®Google Scholar
• Veeraragavan S, Bui N, Perkins JR, et al. Modulation of behavioral phenotypes by a muscarinic M1 antagonist in a mouse model of fragile X syndrome. Psychopharmacology. 2011;217(1):143–151.
   PubMed Web of Science ®Google Scholar
• Xiang Z, Thompson AD, Jones CK, et al. Roles of the M1 muscarinic acetylcholine receptor subtype in the regulation of basal ganglia function and implications for the treatment of Parkinson’s disease. J Pharmacol Exp Ther. 2012;340(3):595–603.
   PubMed Web of Science ®Google Scholar
• Selvakumar GP, Anandhan A, Manivasagam T. Neurotoxicity associated with neuroleptic haloperidol induced tardive dyskinesia in albino mice: protective role of morin. J Pharm Res. 2012;5(7):3633–3639.
   Google Scholar
• Ishola IO, Akinyede A, Adeluwa T, et al. Novel action of vinpocetine in the prevention of paraquat-induced parkinsonism in mice: involvement of oxidative stress and neuroinflammation. Metab Brain Dis. 2018;33(5):1493–1500.
   PubMed Web of Science ®Google Scholar
• Banu Z, Fatima SJ, Fatima A, et al. Phytochemical evaluation and pharmacological screening of anti-Parkinson’s activity of Allium sativum in Swiss/albino mice. IOSR J Pharm. 2016;6(6):1–12.
   Google Scholar
• Pires J, Bonikovski V, Futuro-Neto H. Acute effects of selective serotonin reuptake inhibitors on neuroleptic-induced catalepsy in mice. Braz J Med Biol Res. 2005;38(12):1867–1872.
   PubMed Web of Science ®Google Scholar
• Deacon RM. Measuring motor coordination in mice. J Vis Exp. 2013;4(75):e2609.
   Web of Science ®Google Scholar
• Prakash J, Yadav SK, Chouhan S, et al. Synergistic effect of Mucuna pruriens and Withania somnifera in a paraquat induced Parkinsonian mouse model. Adv Biosci Biotechnol. 2013;4(11):1–9.
   PubMedGoogle Scholar
• Kim J-B, Kopalli SR, Koppula S. Cuminum cyminum Linn (Apiaceae) extract attenuates MPTP-induced oxidative stress and behavioral impairments in mouse model of Parkinson’s disease. Trop J Pharm Res. 2016;15(4):765–772.
   Web of Science ®Google Scholar
• Seibenhener ML, Wooten MC. Use of the open field maze to measure locomotor and anxiety-like behavior in mice. J Vis Exp. 2015;1(96):e52434.
   PubMed Web of Science ®Google Scholar
• Sestakova N, Puzserova A, Kluknavsky M, et al. Determination of motor activity and anxiety-related behaviour in rodents: methodological aspects and role of nitric oxide. Interdiscip Toxicol. 2013;6(3):126–135.
   PubMedGoogle Scholar
• Nade V, Shendye N, Kawale L, et al. Protective effect of nebivolol on reserpine-induced neurobehavioral and biochemical alterations in rats. Neurochem Int. 2013;63(4):316–321.
   PubMed Web of Science ®Google Scholar
• Yadav AV, Nade VS. Anti-dopaminergic effect of the methanolic extract of Morus alba L. leaves. Indian J Pharmacol. 2008;40(5):221–226.
   Google Scholar
• Deacon R, Brook R, Meyer D, et al. Behavioral phenotyping of mice lacking the K ATP channel subunit Kir6.2. Physiol Behav. 2006;87(4):723–733.
   PubMed Web of Science ®Google Scholar
• Takao K, Miyakawa T. Light/dark transition test for mice. J Vis Exp. 2006;1(1):104.
   PubMedGoogle Scholar
• Manikkoth S, Sequeira M, Joy AE, et al. Assessment of brain dopamine levels to evaluate the role of Tylophora indica ethanolic extract on alcohol induced anxiety in Wistar albino rats. J Young Pharm. 2016;8(2):91–95.
   Web of Science ®Google Scholar
• Bhangale JO, Acharya SR. Anti-Parkinson activity of petroleum ether extract of Ficus religiosa (L.) leaves. Adv Pharmacol Sci. 2016;2016:9436106.
   PubMed Web of Science ®Google Scholar
• Lowry OH, Rosebrough NJ, Farr AL, et al. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193(1):265–275.
   PubMed Web of Science ®Google Scholar
• Bais S, Gill N, Kumar N. Neuroprotective effect of Juniperus communis on chlorpromazine induced Parkinson disease in animal model. Chin J Biol. 2015;2015:542542.
   Google Scholar
• Rahman H, Eswaraiah M. Simple spectroscopic methods for estimating brain neurotransmitters, antioxidant enzymes of laboratory animals like mice: a review. Pharmatutor Art. 2008;8:1244.
   Google Scholar
• Poewe W, Seppi K, Tanner CM, et al. Parkinson disease. Nat Rev Dis Primers. 2017;3:17013.
   PubMed Web of Science ®Google Scholar
• Sveinbjornsdottir S. The clinical symptoms of Parkinson’s disease. J Neurochem. 2016;139:318–324.
   PubMed Web of Science ®Google Scholar
• Kulikov A, Bazovkina D, Kondaurova E, et al. Genetic structure of hereditary catalepsy in mice. Genes Brain Behav. 2008;7(4):506–512.
   PubMed Web of Science ®Google Scholar
• Shiotsuki H, Yoshimi K, Shimo Y, et al. A rotarod test for evaluation of motor skill learning. J Neurosci Methods. 2010;189(2):180–185.
   PubMed Web of Science ®Google Scholar
• Pennanen L, Wolfer DP, Nitsch R, et al. Impaired spatial reference memory and increased exploratory behavior in P301L tau transgenic mice. Genes Brain Behav. 2006;5(5):369–379.
   PubMed Web of Science ®Google Scholar
• Rosic G, Joksimovic J, Selakovic D, et al. Anxiogenic effects of chronic exposure to nandrolone decanoate (ND) at supraphysiological dose in rats: a brief report. Neuroendocrinol Lett. 2014;35(703):10.
   Google Scholar
• Takao K, Miyakawa T. Light/dark transition test for mice. J Vis Exp. 2006;1(1):e104.
   PubMedGoogle Scholar
• Surendran S, Rajasankar S. Parkinson’s disease: oxidative stress and therapeutic approaches. Neurol Sci. 2010;31(5):531–540.
   PubMed Web of Science ®Google Scholar
• Schulz JB, Lindenau J, Seyfried J, et al. Glutathione, oxidative stress and neurodegeneration. Eur J Biochem. 2000;267(16):4904–4911.
   PubMedGoogle Scholar
• Jain A, Mårtensson J, Stole E, et al. Glutathione deficiency leads to mitochondrial damage in brain. Proc Natl Acad Sci USA. 1991;88(5):1913–1917.
   PubMed Web of Science ®Google Scholar
• Ribas V, García-Ruiz C, Fernández-Checa JC. Glutathione and mitochondria. Front Pharmacol. 2014;5:151.
   PubMed Web of Science ®Google Scholar
• Droge W. Free radicals in the physiological control of cell function. Physiol Rev. 2002;82(1):47–95.
   PubMed Web of Science ®Google Scholar
• Younus H. Therapeutic potentials of superoxide dismutase. Int J Health Sci. 2018;12(3):88–93.
   PubMed Web of Science ®Google Scholar
• Soltaninejad K, Kebriaeezadeh A, Minaiee B, et al. Biochemical and ultrastructural evidences for toxicity of lead through free radicals in rat brain. Hum Exp Toxicol. 2003;22(8):417–423.
   PubMed Web of Science ®Google Scholar
• Kowalczuk K, Stryjecka-Zimmer M, editors. The influence of oxidative stress on the level of malondialdehyde (MDA) in different areas of the rabbit brain. Ann Univ Mariae Curie Sklodowska Med. 2002;57(2):160–164.
   PubMedGoogle Scholar
• Huang X, Xiaokaiti Y, Yang J, et al. Inhibition of phosphodiesterase 2 reverses gp91phox oxidase-mediated depression- and anxiety-like behavior. Neuropharmacology. 2018;143:176–185.
   PubMed Web of Science ®Google Scholar
• Liberatore GT, Jackson-Lewis V, Vukosavic S, et al. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med. 1999;5(12):1403–1409.
   PubMed Web of Science ®Google Scholar
• Scatton B, Javoy-Agid F, Rouquier L, et al. Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson’s disease. Brain Res. 1983;275(2):321–328.
   PubMed Web of Science ®Google Scholar
• Lloyd KG. CNS compensation to dopamine neuron loss in Parkinson’s disease. In: Messiha FS, Kenny AD, editors. Parkinson’s disease. Advances in experimental medicine and biology. New York (NY): Springer; 1977. p. 255–266.
   Google Scholar
• Kumar A, Singh BK, Ahmad I, et al. Involvement of NADPH oxidase and glutathione in zinc-induced dopaminergic neurodegeneration in rats: similarity with paraquat neurotoxicity. Brain Res. 2012;1438:48–64.
   PubMed Web of Science ®Google Scholar
• Kumar MJ, Nicholls DG, Andersen JK. Oxidative α-ketoglutarate dehydrogenase inhibition via subtle elevations in monoamine oxidase B levels results in loss of spare respiratory capacity: implications for Parkinson’s disease. J Biol Chem. 2003;278(47):46432–46439.
   PubMed Web of Science ®Google Scholar